Servier Updates Progress on OJEMDA in Treating Pediatric Low-Grade Glioma with Four-Year Results
In a significant advancement for pediatric oncology, Servier Pharmaceuticals has announced updated long-term results from the Phase 2 FIREFLY-1 study regarding OJEMDA® (tovorafenib), a treatment for pediatric low-grade glioma (pLGG). This update was shared at the Society for Neuro-Oncology's Annual Meeting held in Philadelphia on November 14, 2026.
The FIREFLY-1 study specifically focuses on patients aged six months to 25 years suffering from relapsed or refractory BRAF-altered pLGG. The newly presented data span a four-year follow-up period that further elucidates the long-term efficacy and safety of OJEMDA. In total, 76 patients who were eligible for efficacy analysis were treated with OJEMDA, which is administered orally once a week in 28-day cycles.
One of the most notable findings from this four-year analysis was the median time to the next treatment, which was found to be 50.9 months. This marks a significant increase from the 42.6 months median established in the previous year's analysis presented at SNO 2025, indicating improved durability of response among patients. Among those who entered an optional post-treatment observation phase, 76% of them managed to remain treatment-free for at least 12 months, while 54% stayed off treatment for two years or more.
The study results not only highlight the effectiveness of OJEMDA but also emphasize the importance of extended treatment intervals, giving patients and their families pivotal insight into treatment options. Dr. Elly Barry, Vice President of Clinical Development at Servier, stated, "With four years of follow-up from FIREFLY-1, we are building a more complete picture of OJEMDA's long-term outcomes, which will help physicians and families make critical treatment decisions."
Safety remained a crucial aspect of the updated findings. The safety profile of OJEMDA was consistent with previous reports, with common Grade 3 treatment-related adverse events observed in greater than 5% of patients, including reduced growth velocity and anemia. Notably, there were no treatment-related deaths, and patients exhibited an overall good tolerance to the drug.
The implications of these findings are profound, especially considering that pediatric low-grade gliomas account for a significant number of childhood brain tumors. A substantial percentage of these tumors are linked to alterations in the BRAF gene, which can hinder treatment options. OJEMDA’s approval was accelerated based on its effectiveness in addressing this specific patient group, and Servier aims to reaffirm this through continued research.
"For children and families living with pediatric low-grade glioma, time spent off treatment is meaningful," explained Dr. Daniel Landi from Duke University and the Duke Cancer Institute, who was involved in the FIREFLY-1 trial. His comment underscores the immediate impacts of treatment duration and patient quality of life, which are critical in planning and managing long-term care strategies for these young patients.
As Servier progresses with further evaluations of OJEMDA, it continues to seek alliances and partnerships aimed at enhancing treatment modalities for pediatric patients facing considerable health challenges. The company's commitment to pushing the boundaries of oncological treatment options reflects a growing trend in the pharmaceutical industry towards personalized medicine that targets specific genetic profiles in cancer treatment.
In summary, the four-year results from the FIREFLY-1 study not only showcase the effectiveness and safety of OJEMDA but also provide essential insights for physicians and families exploring treatment pathways for pediatric low-grade glioma. With ongoing research and development, Servier’s contributions to oncology signify a hopeful future for pediatric patients battling this disease.
The FIREFLY-1 study specifically focuses on patients aged six months to 25 years suffering from relapsed or refractory BRAF-altered pLGG. The newly presented data span a four-year follow-up period that further elucidates the long-term efficacy and safety of OJEMDA. In total, 76 patients who were eligible for efficacy analysis were treated with OJEMDA, which is administered orally once a week in 28-day cycles.
One of the most notable findings from this four-year analysis was the median time to the next treatment, which was found to be 50.9 months. This marks a significant increase from the 42.6 months median established in the previous year's analysis presented at SNO 2025, indicating improved durability of response among patients. Among those who entered an optional post-treatment observation phase, 76% of them managed to remain treatment-free for at least 12 months, while 54% stayed off treatment for two years or more.
The study results not only highlight the effectiveness of OJEMDA but also emphasize the importance of extended treatment intervals, giving patients and their families pivotal insight into treatment options. Dr. Elly Barry, Vice President of Clinical Development at Servier, stated, "With four years of follow-up from FIREFLY-1, we are building a more complete picture of OJEMDA's long-term outcomes, which will help physicians and families make critical treatment decisions."
Safety remained a crucial aspect of the updated findings. The safety profile of OJEMDA was consistent with previous reports, with common Grade 3 treatment-related adverse events observed in greater than 5% of patients, including reduced growth velocity and anemia. Notably, there were no treatment-related deaths, and patients exhibited an overall good tolerance to the drug.
The implications of these findings are profound, especially considering that pediatric low-grade gliomas account for a significant number of childhood brain tumors. A substantial percentage of these tumors are linked to alterations in the BRAF gene, which can hinder treatment options. OJEMDA’s approval was accelerated based on its effectiveness in addressing this specific patient group, and Servier aims to reaffirm this through continued research.
"For children and families living with pediatric low-grade glioma, time spent off treatment is meaningful," explained Dr. Daniel Landi from Duke University and the Duke Cancer Institute, who was involved in the FIREFLY-1 trial. His comment underscores the immediate impacts of treatment duration and patient quality of life, which are critical in planning and managing long-term care strategies for these young patients.
As Servier progresses with further evaluations of OJEMDA, it continues to seek alliances and partnerships aimed at enhancing treatment modalities for pediatric patients facing considerable health challenges. The company's commitment to pushing the boundaries of oncological treatment options reflects a growing trend in the pharmaceutical industry towards personalized medicine that targets specific genetic profiles in cancer treatment.
In summary, the four-year results from the FIREFLY-1 study not only showcase the effectiveness and safety of OJEMDA but also provide essential insights for physicians and families exploring treatment pathways for pediatric low-grade glioma. With ongoing research and development, Servier’s contributions to oncology signify a hopeful future for pediatric patients battling this disease.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.